IGC Pharma (IGC) Shares Outstanding (Weighted Average) (2010 - 2026)

IGC Pharma (IGC) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $98.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $98.2 million, up 23.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $98.2 million (up 23.23% YoY), and the FY2026 annual result was $98.2 million, up 23.23% from the prior year.
• Shares Outstanding (Weighted Average) rose to $98.2 million in Q1 2026 per IGC's latest filing, from $95.0 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $98.2 million in Q1 2026 and troughed at $50.0 million in Q1 2022.
• A 5-year average of $68.0 million and a median of $58.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) advanced 2.83% in 2023, then surged 39.97% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $53.1 million in 2022, then advanced by 7.47% to $57.0 million in 2023, then surged by 36.11% to $77.6 million in 2024, then climbed by 22.42% to $95.0 million in 2025, then climbed by 3.29% to $98.2 million in 2026.
• Business Quant data shows IGC's Shares Outstanding (Weighted Average) at $98.2 million in Q1 2026, $95.0 million in Q4 2025, and $90.5 million in Q3 2025.